Name | Number of supported studies | Average coverage | |
---|---|---|---|
mast cell | 15 studies | 37% ± 12% | |
hematopoietic precursor cell | 3 studies | 28% ± 5% |
Insufficient scRNA-seq data for expression of CTSG at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 75% | 352.43 | 345 / 459 | 67% | 5.40 | 750 / 1118 |
lung | 74% | 390.60 | 427 / 578 | 57% | 3.18 | 663 / 1155 |
bladder | 81% | 545.33 | 17 / 21 | 46% | 4.69 | 234 / 504 |
skin | 66% | 608.96 | 1202 / 1809 | 44% | 3.95 | 208 / 472 |
esophagus | 73% | 485.31 | 1060 / 1445 | 35% | 1.10 | 64 / 183 |
intestine | 64% | 290.38 | 615 / 966 | 39% | 1.82 | 205 / 527 |
prostate | 40% | 121.28 | 97 / 245 | 60% | 2.60 | 303 / 502 |
adipose | 81% | 667.97 | 970 / 1204 | 0% | 0 | 0 / 0 |
pancreas | 9% | 13.76 | 28 / 328 | 70% | 5.55 | 124 / 178 |
stomach | 39% | 133.71 | 141 / 359 | 35% | 1.33 | 100 / 286 |
uterus | 37% | 113.59 | 63 / 170 | 35% | 2.58 | 162 / 459 |
spleen | 72% | 586.60 | 173 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 67% | 3068.84 | 619 / 929 | 0% | 0 | 0 / 0 |
kidney | 15% | 32.56 | 13 / 89 | 50% | 3.49 | 455 / 901 |
tonsil | 0% | 0 | 0 / 0 | 62% | 2.36 | 28 / 45 |
liver | 23% | 46.65 | 53 / 226 | 25% | 2.19 | 103 / 406 |
thymus | 8% | 16.21 | 50 / 653 | 34% | 2.62 | 204 / 605 |
lymph node | 0% | 0 | 0 / 0 | 38% | 1.39 | 11 / 29 |
blood vessel | 27% | 88.66 | 364 / 1335 | 0% | 0 | 0 / 0 |
heart | 18% | 32.28 | 159 / 861 | 0% | 0 | 0 / 0 |
adrenal gland | 0% | 0 | 0 / 258 | 15% | 1.73 | 35 / 230 |
ovary | 8% | 13.62 | 14 / 180 | 7% | 0.24 | 30 / 430 |
muscle | 10% | 17.98 | 82 / 803 | 0% | 0 | 0 / 0 |
brain | 0% | 0.33 | 7 / 2642 | 2% | 0.06 | 16 / 705 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0019221 | Biological process | cytokine-mediated signaling pathway |
GO_0050832 | Biological process | defense response to fungus |
GO_0019731 | Biological process | antibacterial humoral response |
GO_0098786 | Biological process | biofilm matrix disassembly |
GO_0050829 | Biological process | defense response to Gram-negative bacterium |
GO_0050868 | Biological process | negative regulation of T cell activation |
GO_0035590 | Biological process | purinergic nucleotide receptor signaling pathway |
GO_0016485 | Biological process | protein processing |
GO_0022617 | Biological process | extracellular matrix disassembly |
GO_0030168 | Biological process | platelet activation |
GO_0006955 | Biological process | immune response |
GO_0002003 | Biological process | angiotensin maturation |
GO_0050830 | Biological process | defense response to Gram-positive bacterium |
GO_0006508 | Biological process | proteolysis |
GO_1901731 | Biological process | positive regulation of platelet aggregation |
GO_0019538 | Biological process | protein metabolic process |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_0050778 | Biological process | positive regulation of immune response |
GO_0006468 | Biological process | protein phosphorylation |
GO_0002548 | Biological process | monocyte chemotaxis |
GO_0070946 | Biological process | neutrophil-mediated killing of gram-positive bacterium |
GO_0042119 | Biological process | neutrophil activation |
GO_0035578 | Cellular component | azurophil granule lumen |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0005764 | Cellular component | lysosome |
GO_0070062 | Cellular component | extracellular exosome |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0030141 | Cellular component | secretory granule |
GO_0010494 | Cellular component | cytoplasmic stress granule |
GO_0005634 | Cellular component | nucleus |
GO_0008201 | Molecular function | heparin binding |
GO_0008233 | Molecular function | peptidase activity |
GO_0048018 | Molecular function | receptor ligand activity |
GO_0008236 | Molecular function | serine-type peptidase activity |
GO_0089720 | Molecular function | caspase binding |
GO_0005515 | Molecular function | protein binding |
GO_0004252 | Molecular function | serine-type endopeptidase activity |
Gene name | CTSG |
Protein name | Cathepsin G (CG) (EC 3.4.21.20) [Cleaved into: Cathepsin G, C-terminal truncated form] |
Synonyms | |
Description | FUNCTION: Serine protease with trypsin- and chymotrypsin-like specificity . Also displays antibacterial activity against Gram-negative and Gram-positive bacteria independent of its protease activity . Prefers Phe and Tyr residues in the P1 position of substrates but also cleaves efficiently after Trp and Leu . Shows a preference for negatively charged amino acids in the P2' position and for aliphatic amino acids both upstream and downstream of the cleavage site . Required for recruitment and activation of platelets which is mediated by the F2RL3/PAR4 platelet receptor . Binds reversibly to and stimulates B cells and CD4(+) and CD8(+) T cells . Also binds reversibly to natural killer (NK) cells and enhances NK cell cytotoxicity through its protease activity . Cleaves complement C3 . Cleaves vimentin (By similarity). Cleaves thrombin receptor F2R/PAR1 and acts as either an agonist or an inhibitor, depending on the F2R cleavage site . Cleavage of F2R at '41-Arg-|-Ser-42' results in receptor activation while cleavage at '55-Phe-|-Trp-56' results in inhibition of receptor activation . Cleaves the synovial mucin-type protein PRG4/lubricin . Cleaves and activates IL36G which promotes expression of chemokines CXCL1 and CXLC8 in keratinocytes . Cleaves IL33 into mature forms which have greater activity than the unprocessed form . Cleaves coagulation factor F8 to produce a partially activated form . Also cleaves and activates coagulation factor F10 . Cleaves leukocyte cell surface protein SPN/CD43 to releases its extracellular domain and trigger its intramembrane proteolysis by gamma-secretase, releasing the CD43 cytoplasmic tail chain (CD43-ct) which translocates to the nucleus . Cleaves CCL5/RANTES to produce RANTES(4-68) lacking the N-terminal three amino acids which exhibits reduced chemotactic and antiviral activities . During apoptosis, cleaves SMARCA2/BRM to produce a 160 kDa cleavage product which localizes to the cytosol . Cleaves myelin basic protein MBP in B cell lysosomes at '224-Phe-|-Lys-225' and '248-Phe-|-Ser-249', degrading the major immunogenic MBP epitope and preventing the activation of MBP-specific autoreactive T cells . Cleaves annexin ANXA1 and antimicrobial peptide CAMP to produce peptides which act on neutrophil N-formyl peptide receptors to enhance the release of CXCL2 . Acts as a ligand for the N-formyl peptide receptor FPR1, enhancing phagocyte chemotaxis . Has antibacterial activity against the Gram-negative bacteria N.gonorrhoeae and P.aeruginosa . Likely to act against N.gonorrhoeae by interacting with N.gonorrhoeae penA/PBP2 . Exhibits potent antimicrobial activity against the Gram-positive bacterium L.monocytogenes . Has antibacterial activity against the Gram-positive bacterium S.aureus and degrades S.aureus biofilms, allowing polymorphonuclear leukocytes to penetrate the biofilm and phagocytose bacteria . Has antibacterial activity against M.tuberculosis . Mediates CASP4 activation induced by the Td92 surface protein of the periodontal pathogen T.denticola, causing production and secretion of IL1A and leading to pyroptosis of gingival fibroblasts . . |
Accessions | ENST00000216336.3 P08311 |